GlassScriptPhysician profile
Mark Allen Mamros
NPI 1245221829
$14,537.24
in general payments reported to CMS, 2019-2025
41 companies · $2,150 in 2025
The $2,150 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,595 · 2020: $2,042 · 2021: $2,336 · 2022: $1,909 · 2023: $2,142 · 2024: $2,364 · 2025: $2,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,639 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,638.65 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,813.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,798.20 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Pfizer INC. | $1,619.37 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,499.24 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,442.21 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $1,249.97 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $796.48 | 2019-2025 | Otezla, Repatha, Prolia |
| Abbott Laboratories | $601.28 | 2020-2025 | Proclaim, Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $567.00 | 2019-2025 | Spravato, Xarelto |
| Abbvie INC. | $518.69 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $441.70 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $225.35 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $223.52 | 2019-2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Amarin Pharma, INC. | $180.58 | 2020-2022 | |
| Esperion Therapeutics, INC. | $154.49 | 2021-2024 | Nexletol |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mamros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.